Author:
Sharif Z.,Srinivas B.,Tiedt I.,Ryan N.,Awadalla M.,Sullivan V.,Foley D. P.,Gumbrielle T.,McAdam B.,Sheahan R. G.
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Finucane C, Rice C, Kearney F (2011) Prevalence and awareness of atrial fibrillation and estimated stroke risk [CHA2DS2-VASc] in the Irish Longitudinal Study on Ageing [TILDA] Europena Stroke Congress. Karger Publication, Paris
2. Fuster V, Rydén L, Cannon D, Crijns H, Curtis A, Ellenbogen K et al (2011) 2011 ACCF/AHA/HRS focused update incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(10):e269–e367
3. Mehran R, Sunil RV, Deepak BL, Gibson MC, Caixeta A, Eikelboom J et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747
4. Dlott JS, George RA, Odeh M, Kaufman HW, Ansell J, Huang X et al (2014) National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 129:1407–1414
5. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al (2014) Rivaroxaban vs. Vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35:3346–3355. doi:
10.1093/eurheartj/ehu367
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献